Jonathan Jay Mazelsky Form 4 IDEXX LABORATORIES / JAY MAZELSKY ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MAZELSKY JAY

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

04092

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/14/2018		M		544	A	$0	19,467⁽¹⁾	D
Common Stock	02/14/2018		M		403	A	$0	19,870	D
Common Stock	02/14/2018		M		472	A	$0	20,342	D
Common Stock	02/14/2018		M		737	A	$0	21,079	D
Common Stock	02/14/2018		M		459	A	$0	21,538	D
Common Stock	02/14/2018		F		778	D	$178.26⁽²⁾	20,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right-to-buy)	$178.26	02/14/2018		A		25,140		⁽³⁾	02/13/2028	Common Stock	25,140	⁽¹¹⁾	25,140	D
Incentive Stock Option (right-to-buy)	$178.26	02/14/2018		A		560		⁽⁴⁾	02/13/2028	Common Stock	560	⁽¹¹⁾	560	D
Restricted Stock Unit	⁽⁵⁾	02/14/2018		A		2,524		⁽⁵⁾	⁽⁵⁾	Common Stock	2,524	⁽¹¹⁾	11,492	D
Restricted Stock Unit	⁽⁶⁾	02/14/2018		M			544	⁽⁶⁾	⁽⁶⁾	Common Stock	544	⁽¹¹⁾	10,948	D
Restricted Stock Unit	⁽⁷⁾	02/14/2018		M			403	⁽⁷⁾	⁽⁷⁾	Common Stock	403	⁽¹¹⁾	10,545	D
Restricted Stock Unit	⁽⁸⁾	02/14/2018		M			472	⁽⁸⁾	⁽⁸⁾	Common Stock	472	⁽¹¹⁾	10,073	D
Restricted Stock Unit	⁽⁹⁾	02/14/2018		M			737	⁽⁹⁾	⁽⁹⁾	Common Stock	737	⁽¹¹⁾	9,336	D
Restricted Stock Unit	⁽¹⁰⁾	02/14/2018		M			459	⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	459	⁽¹¹⁾	8,877	D

Explanation of Responses:

1. Includes 39 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 29, 2017.

2. Closing price of Issuer's common stock on the NASDAQ market on February 14, 2018.

3. Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2019.

4. Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant.

5. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2019.

6. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split").

7. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split.

8. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split.

9. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017.

10. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018.

11. No applicable.

	/s/ Lily J. Lu, Attorney-in-Fact for Jay Mazelsky	02/16/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Jonathan Jay Mazelsky Form 4IDEXX LABORATORIES / JAY MAZELSKY ownership change